Literature DB >> 22343384

Testicular germ cell tumors: biology and clinical update.

Heather D Mannuel1, Nirupama Mitikiri, Maleha Khan, Arif Hussain.   

Abstract

PURPOSE OF REVIEW: This overview discusses several important developments in testicular germ cell tumors in the past year. RECENT
FINDINGS: Genomic studies continue to investigate gene expression as possible markers for disease relapse and chemotherapy resistance. Optimal treatment strategies for early-stage seminomas are evolving toward surveillance versus chemotherapy and away from radiation, and the role of retroperitoneal lymph node dissection in disseminated nonseminomatous cancers in complete remission is becoming less certain.
SUMMARY: Treatment and surveillance paradigms continue to be defined and refined for both early and late-stage disease as research in these areas continues and the data from multiple large studies mature.

Entities:  

Mesh:

Year:  2012        PMID: 22343384     DOI: 10.1097/CCO.0b013e32835167fc

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  13 in total

1.  Three primary testicular tumours: Trials and tribulations of testicular preservation.

Authors:  Connor M Forbes; Charles Metcalfe; Nevin Murray; Peter C Black
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

2.  LINC00313 regulates the metastasis of testicular germ cell tumors through epithelial-mesenchyme transition and immune pathways.

Authors:  Zhizhong Liu; Bairong Fang; Jian Cao; Qianyin Zhou; Fang Zhu; Liqing Fan; Lei Xue; Chuan Huang; Hao Bo
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells.

Authors:  Mirjam Gerwing; Christine Jacobsen; Sergey Dyshlovoy; Jessica Hauschild; Tina Rohlfing; Christoph Oing; Simone Venz; Jan Oldenburg; Karin Oechsle; Carsten Bokemeyer; Gunhild von Amsberg; Friedemann Honecker
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-16       Impact factor: 4.553

4.  Epigenetic: a molecular link between testicular cancer and environmental exposures.

Authors:  Aurelie Vega; Marine Baptissart; Françoise Caira; Florence Brugnon; Jean-Marc A Lobaccaro; David H Volle
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-29       Impact factor: 5.555

5.  Testicular parenchymal abnormalities in Klinefelter syndrome: a question of cancer? Examination of 40 consecutive patients.

Authors:  Giacomo Accardo; Gianfranco Vallone; Daniela Esposito; Filomena Barbato; Andrea Renzullo; Giovanni Conzo; Giovanni Docimo; Katherine Esposito; Daniela Pasquali
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

6.  miR‑223‑3p regulates cell growth and apoptosis via FBXW7 suggesting an oncogenic role in human testicular germ cell tumors.

Authors:  Jikai Liu; Hao Shi; Xidan Li; Gang Chen; Catharina Larsson; Weng-Onn Lui
Journal:  Int J Oncol       Date:  2016-12-15       Impact factor: 5.650

7.  Loss of miR-514a-3p regulation of PEG3 activates the NF-kappa B pathway in human testicular germ cell tumors.

Authors:  Deniz Mahmut Özata; Xidan Li; Linkiat Lee; Jikai Liu; Dudi Warsito; Praveensingh Hajeri; Isabell Hultman; Omid Fotouhi; Stefan Marklund; Lars Ährlund-Richter; Carl Christofer Juhlin; Catharina Larsson; Weng-Onn Lui
Journal:  Cell Death Dis       Date:  2017-05-04       Impact factor: 8.469

8.  First reported case of paratesticular seminoma in a postpubertal cryptorchid testis.

Authors:  Imad Elhajjar; Khalid Sayyid; Anas Mugharbil; Houssam Khodor Abtar
Journal:  J Surg Case Rep       Date:  2017-06-20

9.  Testicular cancer and cryptorchidism.

Authors:  Lydia Ferguson; Alexander I Agoulnik
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-20       Impact factor: 5.555

Review 10.  Spermatogenesis and cryptorchidism.

Authors:  Giovanni Cobellis; Carmine Noviello; Fabiano Nino; Mercedes Romano; Francesca Mariscoli; Ascanio Martino; Pio Parmeggiani; Alfonso Papparella
Journal:  Front Endocrinol (Lausanne)       Date:  2014-05-01       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.